InflaRx
IFRX

InflaRx (IFRX) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Cantor FitzgeraldMaintainedOverweight$6.00 from $4.00Aug 7, 2026
Raymond JamesUpgradedOutperform → Strong Buy$9.00 from $7.00May 13, 2026
Cantor FitzgeraldMaintainedOverweight$4.00 from $2.00May 11, 2026
HC Wainwright & Co.MaintainedBuy$8.00 from $6.00May 11, 2026
GuggenheimMaintainedBuy$14.00Apr 21, 2026
GuggenheimMaintainedBuy$14.00 from $22.00Mar 20, 2026
HC Wainwright & Co.MaintainedBuy$6.00Dec 30, 2025
Leerink PartnersDowngradedOutperform → Market Perform$2.00 from $5.00Dec 3, 2025
GuggenheimMaintainedBuy$22.00 from $10.00Nov 10, 2025
HC Wainwright & Co.Initiated CoverageBuy$6.00Sep 2, 2025
OppenheimerMaintainedOutperform$3.00 from $6.00May 29, 2025
OppenheimerInitiated CoverageOutperform$6.00May 8, 2025
Cantor FitzgeraldInitiated CoverageOverweight$10.00Apr 29, 2025
GuggenheimMaintainedBuy$10.00 from $7.00Mar 26, 2025
HC Wainwright & Co.MaintainedBuy$8.00Mar 21, 2025
HC Wainwright & Co.MaintainedBuy$8.00Mar 7, 2025
HC Wainwright & Co.MaintainedBuy$8.00Jan 16, 2025
HC Wainwright & Co.MaintainedBuy$8.00Dec 20, 2024
HC Wainwright & Co.MaintainedBuy$8.00Nov 15, 2024
HC Wainwright & Co.MaintainedBuy$8.00Nov 11, 2024

Frequently asked questions

  • What is the latest analyst rating on IFRX?

    On Aug 7, 2026, Cantor Fitzgerald maintained InflaRx at Overweight with a price target of $6.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.